[go: up one dir, main page]

PE20050265A1 - Derivados de acido alquilarilo como inhibidores de diacilglicerol aciltransferasa tipo 1 (dgat-1) - Google Patents

Derivados de acido alquilarilo como inhibidores de diacilglicerol aciltransferasa tipo 1 (dgat-1)

Info

Publication number
PE20050265A1
PE20050265A1 PE2004000471A PE2004000471A PE20050265A1 PE 20050265 A1 PE20050265 A1 PE 20050265A1 PE 2004000471 A PE2004000471 A PE 2004000471A PE 2004000471 A PE2004000471 A PE 2004000471A PE 20050265 A1 PE20050265 A1 PE 20050265A1
Authority
PE
Peru
Prior art keywords
alkyl
derivatives
diacilglicerol
dgat
inhibitors
Prior art date
Application number
PE2004000471A
Other languages
English (en)
Inventor
Roger Smith
Ann-Marie Campbell
Miao Dai
Derek Lowe
Ning Su
Mingbao Zhang
Lei Zhu
Gan Wang
Stephen O'connor
Susan Jenkins
Philip Coish
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of PE20050265A1 publication Critical patent/PE20050265A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE ALQUILARILO DE FORMULA I DONDE Q ES O, S, NR5; A ES UNA LIGADURA SUSTITUIDA POR R8; R1 Y R2 SON H, HALO, ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS; R3 ES H, ALQUILO C1-C6 SUSTITUIDO POR OH, FENILO CON ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS; R4 ES H, NITRO, ALQUILO C1-C6; R3 Y R4 JUNTO AL ATOMO DE C A LOS QUE ESTAN UNIDOS FORMAN UN ANILLO DE BENCENO CON HALO, ALQUILO C1-C6, ENTRE OTROS; R5 ES H, ALQUILO C1-C6; R6 ES H; R7 ES H, ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS; R8 ES ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS ACIDO 4-[4'-(1H-BENCIMIDAZOL-2-ILAMINO)-1,1'-BIFENIL-4-IL]-2,2-DIMETIL-4-OXOBUTANOICO, ACIDO 4-{4'-[(5-METOXI-1H-BENCIMIDAZOL-2-IL)AMINO]-1,1'-BIFENIL-4-IL}-2,2-DIMETIL-4-OXOBUTANOICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS DERIVADOS DE ALQUILARILO SON INHIBIDORES DE DIACILGLICEROL O-ACILTRANSFERASA TIPO 1 (DGAT-1) Y SON UTILES EN EL TRATAMIENTO DE LA OBESIDAD
PE2004000471A 2003-05-09 2004-05-07 Derivados de acido alquilarilo como inhibidores de diacilglicerol aciltransferasa tipo 1 (dgat-1) PE20050265A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46961903P 2003-05-09 2003-05-09

Publications (1)

Publication Number Publication Date
PE20050265A1 true PE20050265A1 (es) 2005-06-03

Family

ID=33452304

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000471A PE20050265A1 (es) 2003-05-09 2004-05-07 Derivados de acido alquilarilo como inhibidores de diacilglicerol aciltransferasa tipo 1 (dgat-1)

Country Status (24)

Country Link
US (5) US7091228B2 (es)
EP (1) EP1633722B1 (es)
JP (1) JP4759517B2 (es)
KR (1) KR20060009916A (es)
CN (1) CN1816531A (es)
AR (1) AR044152A1 (es)
AT (1) ATE518841T1 (es)
AU (1) AU2004238258A1 (es)
BR (1) BRPI0410170A (es)
CA (1) CA2524470A1 (es)
CL (1) CL2004000969A1 (es)
EC (1) ECSP056210A (es)
ES (1) ES2369220T3 (es)
GT (1) GT200400092A (es)
MA (1) MA27843A1 (es)
MX (1) MXPA05012061A (es)
NO (1) NO20055832L (es)
NZ (1) NZ543993A (es)
PE (1) PE20050265A1 (es)
RU (1) RU2357959C2 (es)
TW (1) TW200510334A (es)
UY (1) UY28314A1 (es)
WO (1) WO2004100881A2 (es)
ZA (1) ZA200509883B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357015T3 (es) * 2004-10-15 2011-04-15 Bayer Healthcare Llc Preparación y uso de derivados bifenil-4-ilcarbonilaminoácido para el tratamiento de la obesidad.
JP2008523133A (ja) 2004-12-14 2008-07-03 アストラゼネカ アクチボラグ Ｄｇａｔ阻害剤としてのオキサジアゾール誘導体
WO2006082952A1 (ja) * 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited アミド化合物
KR100883694B1 (ko) * 2005-02-07 2009-02-12 에프. 호프만-라 로슈 아게 디아실글리세롤 아실트랜스퍼라제 억제제
AU2006236155A1 (en) * 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
MX2007015759A (es) * 2005-06-11 2008-02-21 Astrazeneca Ab Derivados de oxadiazol como inhibidores de diacilglicerol aciltransferasa (dgat).
US20100016295A1 (en) * 2005-07-29 2010-01-21 Bayer Healthcare Llc Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity
WO2007023882A1 (ja) * 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Ｐｐａｒアゴニスト活性を有する誘導体
AU2006316560B2 (en) 2005-11-28 2011-06-16 Madrigal Pharmaceuticals, Inc. Inhibitors of diacyglycerol acyltransferase (DGAT)
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
EP2301923B1 (en) * 2006-03-31 2016-06-08 Novartis AG Pyridine derivatives as dgat inhibitors
US20080293785A1 (en) * 2006-04-11 2008-11-27 Connolly Peter J Substituted benzothiazole kinase inhibitors
US20070254952A1 (en) * 2006-04-21 2007-11-01 Yuguang Wang Cannabinoid receptor modulators
WO2007137107A2 (en) * 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007137103A2 (en) * 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
US8003676B2 (en) 2006-05-30 2011-08-23 Astrazeneca Ab 1,3,4-oxadiazole derivatives as DGAT1 inhibitors
ATE492541T1 (de) * 2006-05-30 2011-01-15 Astrazeneca Ab Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase
JP2009539816A (ja) * 2006-06-06 2009-11-19 アストラゼネカ アクチボラグ 化学化合物
CN101460492A (zh) * 2006-06-08 2009-06-17 阿斯利康(瑞典)有限公司 苯并咪唑及其治疗糖尿病的用途
GB0611506D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) * 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
WO2008047694A1 (fr) * 2006-10-13 2008-04-24 Aska Pharmaceutical Co., Ltd. Procédé de fabrication d'un composé benzothiazole
NZ597247A (en) 2006-11-29 2013-06-28 Abbott Lab Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
KR20100017508A (ko) 2007-04-30 2010-02-16 아보트 러보러터리즈 디아실글리세롤 ｏ-아실트랜스퍼라제 타입 1 효소의 억제제
NZ580662A (en) 2007-04-30 2012-01-12 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme used in manufacture of medicament for treatment of diabetes or lipid associated disorders
ES2483898T3 (es) * 2007-06-08 2014-08-08 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
AU2008258487B2 (en) 2007-06-08 2012-11-15 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009081195A1 (en) 2007-12-20 2009-07-02 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
US8394823B2 (en) * 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
JP5579170B2 (ja) 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｄｇａｔ阻害剤とｐｐａｒ作動薬を含有する薬剤組み合わせ物
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2749700A1 (en) * 2009-01-23 2010-07-29 Msd K.K. Benzodiazepin-2-on derivatives
AR076126A1 (es) 2009-03-18 2011-05-18 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
CA2764013A1 (en) 2009-06-19 2010-12-23 Astrazeneca Ab Pyrazine carboxamides as inhibitors of dgat1
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011031628A1 (en) 2009-09-14 2011-03-17 Schering Corporation Inhibitors of diacylglycerol acyltransferase
RU2012149806A (ru) * 2009-11-05 2014-05-27 Пирамал Энтерпрайзис Лимитед Карбоксиоксазольные или тиазольные соединения в качестве ингибиторов dgat-1, пригодные для лечения ожирения
EA202092673A3 (ru) * 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
WO2011123401A1 (en) 2010-03-30 2011-10-06 Novartis Ag Uses of dgat1 inhibitors
WO2012064569A1 (en) * 2010-11-08 2012-05-18 Merck Sharp & Dohme Corp. Imidazole derivatives
DK2651915T3 (en) * 2010-12-17 2016-07-18 Mitsubishi Tanabe Pharma Corp Continuous arycyclic compound
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102757420B (zh) * 2011-04-28 2015-02-04 中国科学院上海药物研究所 联杂芳基羧酸类化合物、其制备方法,包含该化合物的药物组合物、及用途
KR20130013199A (ko) 2011-07-27 2013-02-06 한미약품 주식회사 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013039140A1 (ja) * 2011-09-14 2013-03-21 第一三共株式会社 縮合へテロ環誘導体
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013056679A1 (en) * 2011-10-21 2013-04-25 Beijing Hanmi Pharmaceutical Co., Ltd Novel heteroaryl-amino derivatives
AU2013245353A1 (en) 2012-04-06 2014-09-25 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
US9546155B2 (en) 2012-06-15 2017-01-17 Mitsubishi Tanabe Pharma Corporation Aromatic heterocyclic compound
JP5721032B2 (ja) * 2012-06-15 2015-05-20 田辺三菱製薬株式会社 医薬組成物
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CR20160405A (es) 2014-03-17 2016-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
HRP20210145T1 (hr) * 2016-09-09 2021-03-05 F. Hoffmann - La Roche Ag Postupak za dobivanje 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-b;3',4'-d]pirola
EP3305786A3 (de) 2018-01-22 2018-07-25 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave
EP4039676A4 (en) * 2019-10-02 2024-04-03 Klotho Sciences COMPOUND FOR INDUCING THE EXPRESSION OF AN ANTI-AGEING GENE KLOTHO AND USE THEREOF
KR102863043B1 (ko) 2020-01-29 2025-09-23 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물
WO2022109182A1 (en) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2112840A1 (de) 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-buttersaeuren,ihre Salze und Ester
BE603739A (es) * 1960-05-13
US3299087A (en) * 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
US3997589A (en) 1971-03-17 1976-12-14 Boehringer Ingelheim Gmbh 4-(2'-Fluoro-4-biphenylylr-4-oxo-butyric acid and esters and salts thereof
DE2112716A1 (de) 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
DE2112715A1 (de) 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-hydroxybuttersaeuren,ihre Salze,Ester und Lactone
US4021479A (en) 1971-03-17 1977-05-03 Boehringer Ingelheim Gmbh Derivatives of 4-(4-biphenylyl)-butyric acid
DE3825617C2 (de) 1988-07-28 1993-11-18 W D Schumacher Einrichtung zur Entfernung von Schmutz oder anderen Verunreinigungen
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
TW259786B (es) * 1992-12-17 1995-10-11 Sankyo Co
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
GB2276161A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5886022A (en) * 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
TW429256B (en) * 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
DE69939426D1 (de) 1998-06-24 2008-10-09 David Gladstone Inst Diacylglycerin o-acyltransferase
DE69941390D1 (de) 1998-07-02 2009-10-22 Calgene Llc Diacylglyzerin-acyltransferase proteine
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
EP1031349A1 (en) 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
MXPA01012317A (es) 2000-12-28 2002-07-22 Warner Lambert Co Prueba de aciltransferasa del diacilglicerol (dgat).

Also Published As

Publication number Publication date
NZ543993A (en) 2009-06-26
UY28314A1 (es) 2004-11-30
ECSP056210A (es) 2006-04-19
AR044152A1 (es) 2005-08-24
CL2004000969A1 (es) 2005-04-22
US20040224997A1 (en) 2004-11-11
JP4759517B2 (ja) 2011-08-31
JP2007502862A (ja) 2007-02-15
ES2369220T3 (es) 2011-11-28
RU2357959C2 (ru) 2009-06-10
ZA200509883B (en) 2007-03-28
ATE518841T1 (de) 2011-08-15
EP1633722A4 (en) 2008-07-02
CN1816531A (zh) 2006-08-09
RU2005138134A (ru) 2006-06-27
MXPA05012061A (es) 2006-02-22
EP1633722B1 (en) 2011-08-03
AU2004238258A1 (en) 2004-11-25
US8013166B2 (en) 2011-09-06
WO2004100881A2 (en) 2004-11-25
CA2524470A1 (en) 2004-11-25
MA27843A1 (fr) 2006-04-03
TW200510334A (en) 2005-03-16
KR20060009916A (ko) 2006-02-01
US20060194859A1 (en) 2006-08-31
BRPI0410170A (pt) 2006-05-16
NO20055832D0 (no) 2005-12-08
NO20055832L (no) 2006-02-03
US20090253762A1 (en) 2009-10-08
EP1633722A2 (en) 2006-03-15
WO2004100881A3 (en) 2005-02-03
US7968576B2 (en) 2011-06-28
GT200400092A (es) 2005-01-11
US20090197795A1 (en) 2009-08-06
US7091228B2 (en) 2006-08-15
US7423156B2 (en) 2008-09-09
US20090270468A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
PE20050265A1 (es) Derivados de acido alquilarilo como inhibidores de diacilglicerol aciltransferasa tipo 1 (dgat-1)
PE20040600A1 (es) Derivados de triazol como antagonistas del receptor de taquicinina
CO4820443A1 (es) Composicion herbicida
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
BR0114657A (pt) Compostos de benzamida e seu uso
AR036111A1 (es) Compuesto de n-[alfa-aminoalcanoil]-3-fluorpirrolidina; composicion farmaceutica formulada con dicho compuesto; su uso en la preparacion de dicha composicion y metodo para el tratamiento de la diabetes tipo 2 utilizando dicho compuesto
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20030440A1 (es) Fenilsulfonamidas como antagonistas de ccr3
AR045955A1 (es) Compuestos benzoimidazolicos
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
AR036778A1 (es) Compuesto derivado de oxazolidinona sustituida y/o isoxazolina sustituida, profarmacos, su uso en la fabricacion de medicamentos, composicion farmaceutica y proceso para prepararlos
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
DK0442820T3 (da) Benzimidazol- og azabenzimidazolderivater, som er thromboxan-receptor-antagonister, fremgangsmåder til deres fremstilling, syntesemellemprodukter og farmaceutiske præparater med indhold deraf
BR9307580A (pt) Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
NO983493L (no) Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike
AR039562A1 (es) Compuestos oxo-azabiciclicos
PE20030134A1 (es) Derivados de oxazolidinonas como antibacterianos
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
PE20030629A1 (es) Sal sodica cristalina y procedimiento para su preparacion
MY141579A (en) Pyrrolidine-2-one derivatives, processes for their preparation, composition containing them and their use as factor xa inhibitors

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed